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The genome editing platforms currently in use have
revolutionized the field of genetics. At an accelerating
rate, these tools are entering areas with direct impact
on human well being. Here, we discuss applications in
agriculture and in medicine, and examine some
associated societal issues.
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germline genome editing, regulationthere are any other factors that point towards promot-
ing or impeding its use. In concert with several recentIntroduction
The genome editing technologies that are causing a
current stir began life quietly in the 1990s, but are enjoy-
ing a remarkable surge, largely owing to the introduction
of the CRISPR-Cas tools in 2012 [1–3]. The simplicity of
that platform, compared with the earlier zinc-finger nucle-
ases (ZFNs) and transcription activator-like effector nucle-
ases (TALENs), has led to its rapid adoption and, in turn,
to consideration of the uses to which it could readily be
put. The power of these technologies derives from the fact
that they allow directed modification of specific DNA se-
quences at their normal chromosomal locations, including
changes as small as a single base pair or as dramatic as
large deletions, insertions or translocations. The technolo-
gies have been used to produce models of human disease
in experimental organisms and to explore fundamental
gene function.
Current applications of genome editing include some
with potential impact on the security of the world food
supply and on clinical therapies. In fact, essentially the
full range of uses — including agricultural and clinical,
as well as potential nefarious ones — was already evident
with earlier technologies, and many of the societal issues* Correspondence: dana@biochem.utah.edu
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germline modification were partially addressed, even be-
fore the efficient nuclease-based technologies arrived.
Here, we discuss briefly the capabilities of the genome
editing technologies, their current and envisioned uses,
and the relevant regulatory policies that are meant to re-
flect the public interest. Ultimately, the issues are whether
the beneficial uses of genome editing are adequately
safe and acceptable, whether regulatory oversight ap-
propriately balances realistic risk assessment with
achievement of the anticipated benefits, and whether
perspectives, we focus particularly on the potential for
modification of the human germline.The technologies
It might not be widely appreciated that all the genome
editing reagents accomplish is to make breaks in chromo-
somal DNA [4–6]. The ZFNs, TALENs and RNA-guided
nucleases of the CRISPR-Cas system are fundamentally
just nucleases. Their power comes from the fact that they
can all be designed to make a break very specifically at
essentially any target sequence that is chosen by the
experimenter. This allows the modification of practically
any locus in the genome of any organism.
The modifications themselves depend entirely on the
DNA repair capabilities of the cells in which the breaks
are made [5]. In simple terms, essentially all cells and or-
ganisms rely on two broad types of process to repair
double-strand breaks (Fig. 1). The ends at the break can
simply be rejoined, either precisely or imprecisely, by a
mechanism called nonhomologous end joining (NHEJ).
Imprecise joining leaves behind small insertions or dele-
tions (indels) at the break site, generating targeted muta-
tions. When these are in coding sequences, they often
constitute a knockout of gene function. Alternatively, re-
pair can proceed by copying sequences from a template
that has extensive homology with sequences around the
break. This homology-dependent repair (HDR) wouldarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Pathways of repair after nuclease cleavage. In a cell with
many chromosomes, a unique site on one chromosome is targeted
for cleavage by a programmable nuclease (red ‘lightning bolt’). Cells
repair the break either by non-homologous end joining (NHEJ),
which can leave small insertions or deletions (indels), or
homology-dependent repair (HDR) using a template supplied by
the experimenter. Although mitotic chromosomes are illustrated
here, it is unlikely that these processes occur specifically in mitosis
Fig. 2 Illustration of one-cell embryo injection for CRISPR-Cas
modification of a mammalian embryo. The nuclease components
(the nuclease Cas9, and the short guide RNA (sgRNA)) are injected
into a fertilized egg that has two nuclei derived from the male and
female parents. The targeted modification (indicated by ‘x’) can
occur in one or both nuclei, and the zygote proceeds to divide
and form subsequent embryo stages
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matid as a template, but it can be diverted to use a DNA
supplied by the experimenter that carries desired sequence
changes, leading to targeted sequence replacement.
These repair mechanisms are common to a wide range
of organisms, but, to benefit from their activity, the nu-
clease and template must be delivered effectively to the
cells of interest. The delivery methods and the editing
outcome will depend on the biology of the system. For
example, the nucleases can be introduced into some or-
ganisms, including most mammals, by direct embryo in-
jection, in conjunction with in vitro fertilization (Fig. 2).
In most plants, however, delivery is more challenging
(see section below on Genetically engineered organisms
and their regulation). As a second illustration of the in-
fluence of the biological system, the balance between
NHEJ and HDR varies considerably among cell types
and organisms. HDR represents a significant proportion
of events in rapidly dividing cells, but typically not in
primary human cell cultures, and this limits the ability
to make subtle intentional changes.
All of the nuclease platforms are capable of high speci-
ficity, but none of them is perfect. In the process of mak-
ing desired changes at the designed target, unintentional
changes can be induced elsewhere in the genome by
cleavage and NHEJ repair at secondary sites [5]. This is
a modest hazard in experimental organisms, where inde-
pendent events can be compared, the genetic background
can be cleaned up by out-breeding and conclusions can
be validated by complementation with a wild-type se-
quence. There are also methods for detecting, locatingand quantifying these off-target effects [7]. In applica-
tions to human therapy, we need to be assured that the
treatment will not cause a new condition while curing
the one intentionally addressed. Fortunately, the ability
to direct subtle changes to the endogenous target avoids
some of the dangers inherent in earlier methods for deliv-
ery of therapeutic genes (see below).
Applications to agriculture
The current world food supply is inadequate, and the
situation will get worse as populations continue to grow
[8]. There are other serious considerations, including de-
mands on uncertain water supplies, changing climates,
and animal welfare. Genome editing will not provide
general solutions to these broader issues, but there are
some areas where the technology can help.
Applications to plants, including crops, are covered in
detail below, but suffice it to say here that crops provide
the bulk of nutrition for the world population. Any im-
provements in nutritional value and resilience would be
welcome in many species, and some of these can be
approached sensibly through genome editing [9].
In the realm of livestock, genome editing is just begin-
ning to be applied, so specific applications are still emer-
ging. One example that is being pursued currently is the
genetic dehorning of dairy cattle [10]. Because the cattle
are kept in close quarters, dairy farmers typically remove
their horns by physical methods that are invasive, painful
and expensive. Natural genetic variants, called polled,
exist in some beef breeds [11]. This trait could, in
principle, be transferred to dairy herds by traditional
breeding, but it would be prohibitively time-consuming
and expensive to do so as it would be necessary to per-
form extensive additional breeding to restore favorable
dairy traits. Because the responsible DNA sequence
change has been characterized, it is possible to use gen-
ome editing [12] to introduce the variant into existing
herds without affecting their other, beneficial, traits. The
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dairy genomes, with no additional DNA being present.
Another application envisioned for cattle and for pigs
is mutation of the myostatin gene, which negatively
regulates the production of skeletal muscle. Natural mu-
tations in this gene exist [13]. Homozygous mutants are
rather grotesquely muscled, but heterozygotes are largely
normal, except that they have approximately 7 % more
muscle mass in the form of lean, marketable meat. Such
mutations can readily be produced in cells [14, 15], and
a recent news report indicates that live pigs have been
generated carrying myostatin mutations [16]. These gen-
etic maneuvers can be performed independently in
breeds that carry adaptions to different environmental
conditions, such as heat or cold tolerance, drought toler-
ance, or resistance to particular infectious agents. In
addition, as the genetic variants responsible for those ad-
aptations are identified, they could also be introduced
into new breeds by genome editing.
Genetically engineered organisms and their
regulation
Quite literally, genome-edited animals and plants are gen-
etically modified organisms — GMOs — but they differ
from the controversial genetically engineered crops cur-
rently under cultivation. The latter carry transgenes
imported from other species, commonly from bacteria. By
contrast, genome editing allows the precise inactivation of
an endogenous gene, the conversion of an existing allele
to a more favorable one, or the precise insertion of an
identified variant into additional breeds. The animal and
plant products of these modifications are essentially iden-
tical to ones that could, and in some cases do, occur nat-
urally or could be created by traditional breeding
methods. Because editing is performed in a hit-and-run
fashion — the nucleases do their job and then are de-
graded within cells — no trace of the reagents remains in
the organism. For considerations of safety, it seems sens-
ible to regulate based on the product's characteristics,
independent of the process used to develop them.
In the USA, genetically engineered plants are subject to
regulation by three federal agencies: The United States
Department of Agriculture (USDA) Animal and Plant
Health Inspection Service, the Department of Health and
Human Services' Food and Drug Administration (FDA),
and the United States Environmental Protection Agency
(EPA). If a major federal action results, there might also
be a requirement for public review and consultation under
the National Environmental Policy Act [17].
Since the development in the 1980s of the ‘coordinat-
ing framework’, it has been US policy to regulate bio-
technology products based on their characteristics and
intended uses, and not by their method of production,
even when that method involves novel technologies. Theapproach has been mirrored in other areas as well.
Nanotechnology, for example, is the subject of a great
deal of discussion among the many departments for
which it is relevant, ranging from workplace protections
to environmental safety to evaluation of new drugs, de-
vices and foods, but in the end, each nanotechnology
product is regulated according to the product’s standard
pathway.
As a general rule, products are regulated under exist-
ing law, and the method of production is relevant only
to the extent that it affects the considerations required
under existing law. For example, the USDA will look to
see whether a new kind of plant constitutes a ‘plant pest’,
and will examine the extent to which the engineering
changes characteristics of the plant, which will be exam-
ined to see whether the organism now grows, spreads or
competes in ways that would make any other plant a
‘pest’. The EPA looks at the safety of pesticides, and will
similarly look at the safety of ‘plant-incorporated protec-
tants’ produced through genetic engineering. For the
FDA, reviewing the safety of a human or animal drug
includes looking at long-term effects, including the sta-
bility or off-target effects of any genetic changes. And if
a vector (regarded as an animal drug) is used for a food
animal, the product will be reviewed for safety in the
animal, the environment and the resulting food.
To some extent, this differs from European approaches
[17–19], where the use of genetic engineering — regard-
less of the resulting characteristics of the product — will
trigger special requirements, for example, product label-
ing. In general, there is greater pre-market control,
whether for deliberate release of organisms or sale for
food and animal feed, based on a more aggressive inter-
pretation of the precautionary principle and fewer limi-
tations on government authority to prohibit or compel
commercial speech. The situation is complicated by the
division of authority between the governmental bodies
of the European Union and those of individual member
states, and recent debates have focused on the degree of
autonomy that should be allowed at the national level.
The researchers and companies, in the USA and else-
where, who are dedicated to genome editing of crops
and livestock certainly hope that the simplicity, precision
and naturalness of the modifications will lead to public
acceptance of the products. Much of the opposition to
genetically engineered organisms, however, is political,
economic and visceral, and the scientific distinctions
might not carry much weight. Economic concerns en-
compass distrust of corporate agriculture, resistance to
awarding intellectual property rights for seeds, and fear
of disrupting local industries dependent on wild-caught
or heirloom varieties of animals and plants. They also
encompass fear of unintended ecological consequences.
And beyond this, for many people there is an emotional
Carroll and Charo Genome Biology  (2015) 16:242 Page 4 of 9attachment to a particular conception of nature and of
genetics, one that might not conform to biological defi-
nitions, but which is part of a world view in which man-
made modifications and products using modern genetics
are seen in part as evidence of hubris. Therefore, while
genetically modified crops are demonstrably safe to eat,
both by livestock and people, it might be difficult to
overcome a fundamental resistance to intentional gen-
etic manipulation, despite the fact that selective breeding
by humans has produced the genomes of essentially all
the foods we currently consume.
Applications to medicine
Ever since the discovery of specific human disease genes,
scientists have harbored hopes that the responsible mu-
tations could be reversed with molecular approaches. In
cases where a gene product is frankly missing, it is pos-
sible to provide a functional copy of the gene. While this
has been successful in a few cases, several challenges
stand in the way of facile use of the approach, including
delivery of the gene to the affected cells, safe and effi-
cient integration into the genome, and immunological
reaction to the therapeutic protein itself or the vector
used for delivery. Two early clinical trials dramatically il-
lustrate the hazards. In tests of gene therapy for orni-
thine transcarbamylase deficiency, a teenager died as a
result of a severe immune reaction to the adenoviral vec-
tor [20] after receiving a very high dose of the thera-
peutic vector in an attempt to deliver a curative level of
gene expression.
A program to treat cases of X-linked severe combined
immunodeficiency (SCID-X1) relied on an ex vivo ap-
proach, delivering the missing IL-2Rγ gene to bone
marrow stem cells from the patients, followed by re-
implantation. This led to sustained reversal of the im-
mune deficiency in a majority of the recipients [21]. In
several cases, however, leukemias developed owing to
activation of the LMO2 oncogene caused by integration
of the retroviral vector in its vicinity [22]. The fre-
quency of the offending integrations was very low in
the treated bone marrow cells, but they had a signifi-
cant growth advantage once expanded and returned to
the patient’s body. This experience put a damper on
therapies using retroviral vectors.
More recently and for the first time, a gene therapy
procedure has been approved in Europe for treatment of
patients. Glybera delivers the gene encoding lipoprotein
lipase in an adeno-associated virus (AAV) vector to
muscle tissue in patients lacking this enzyme [23]. AAV
has the advantage that it does not integrate into the hu-
man genome, or does so rarely at an innocuous site, so
it is judged safer than retroviral vectors.
Genome editing has several advantages relative to
vector-mediated gene delivery: (i) in most cases, a mutantgene will be corrected, or otherwise modified, at its nor-
mal genomic locus, so random integration is not an issue;
(ii) because editing occurs at the normal locus, no se-
quences driving expression need to be present on any
donor DNA, and regulation of the target gene will be nor-
mal; (iii) off-target mutagenesis, if it occurs, is unlikely to
activate a gene, as was seen in the SCID-X1 trials; and (iv)
the editing materials will be present only transiently in the
cells, and only the edit itself will persist.
One example of genome editing applied to the clinic
has already been published [24]. It was based on the ob-
servation that some humans naturally lack a functional
gene for CCR5, the required co-receptor in T cells for
most strains of HIV-1. Although these people can be in-
fected with the virus, the immune system is not depleted
because their T cells are resistant to killing. A pair of
ZFNs that was very highly evolved for efficacy and speci-
ficity was used to treat T cells derived from HIV-infected
patients during laboratory culture. The CCR5 gene was
mutated in a substantial fraction of the cells, including
some biallelic knockouts. The treated cells were returned
to the patient from whom they were derived. Although
therapeutic value was not the goal of this phase I trial,
the procedure showed no ill effects, and the mutated
cells persisted for a remarkable period of time. An ex-
tension of this approach will likely apply the same treat-
ment to bone-marrow-derived hematopoietic stem cells
(HSCs), in which successful knockout of CCR5 would
provide a long-term reconstitution of an HIV-resistant T
cell arm of the immune system.
Like this trial and the one for SCID-X1, the future
therapeutic applications that are easiest to envision are
ones involving ex vivo treatment. The treated cells can
be analyzed in vitro to ensure that the desired modifica-
tion has been made, and successfully modified cells
could potentially be enriched, before implantation in the
patient. If, and when, therapies based on stem cells other
than HSCs are developed, genome editing and autolo-
gous transplantation will be useful there as well. Direct
delivery to tissues in the body, by contrast, presents
serious challenges. Consider, for example, the case of
cystic fibrosis, where multiple tissues are affected, and
success would require delivery to epithelial cells deep
in the lung.
Human germline modification
We must start this section by pointing out that discus-
sions of the scientific and ethical considerations surround-
ing genetic modification of the human germline were
initiated long before current technologies were envisioned
(e.g., see [25]). The apparent facility with which such mod-
ifications can now be accomplished has made discussion
of the issues more urgent. Historically, essentially all
participants in these discussions have called for broad
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spectives: scientific, philosophical and societal. This call
was reiterated very recently by members of both industry
and research communities [26, 27], and has become the
subject of a joint initiative by the National Academy of
Sciences and the National Academy of Medicine that will
focus equally on domestic and transnational possibilities
and concerns [28].
The methods for performing germline editing on nu-
clear DNA are already available. They have been applied
to other mammals, including primates [29–31], and one
account of their use in non-viable human embryos has
been published [32]. To achieve a transgenerational modi-
fication of the germline, two approaches are possible, both
performed in conjunction with in vitro fertilization and
then gestation of the resulting embryo. One is to make the
desired modifications in cultured cells and transplant a
nucleus from a successfully modified cell into an enucle-
ated egg fertilized in vitro. This is called somatic cell nu-
clear transfer (SCNT) and is sometimes referred to as
‘cloning’. This approach can be readily dismissed, at least
for current purposes, because experience with several dif-
ferent animal species has shown that it is associated with
a very high frequency of developmental defects, presum-
ably owing to the difficulty of reprogramming a somatic
cell nucleus for all developmental functions.
The second approach is to deliver the editing materials
(nuclease with or without donor DNA) directly to a fer-
tilized egg and let the modifications take place there in
the maternal and paternal genomes (Fig. 2). Implant-
ation of eggs fertilized in vitro shows a high success rate
that would probably not be much affected by the editing
procedure itself. With injection, there is a significant
chance that the embryos will be mosaic for the modifica-
tion, if some nuclease cutting occurs after cell division
and the efficiency is less than 100 %. There is also the
danger of off-target mutagenesis, and it will be challen-
ging to assess this at a sufficiently early stage.
In the long run, germline editing might proceed by
modifying gametes before fertilization. This will require
not only effective methods for delivering the reagents,
but an understanding of the DNA repair capabilities of
sperm and eggs.
Ethical considerations
For the moment, despite the plethora of other possible
applications, much of the most impassioned discussion
about CRISPR-Cas9 has focused on its potential for edit-
ing the nuclear DNA of human gametes or embryos —
so-called germline editing. The critiques largely break
down into two large categories that are used in ethical
analyses of many different kinds of technologies and
human actions. The first — which is present in some
religious analyses, but is also the hallmark of secularapproaches — might be called consequentialist [33]. On
the one hand, it focuses on the possibilities for improv-
ing the human condition, through the elimination of
deleterious characteristics or mutations. It might allow
people who carry such traits to have children to whom
they are genetically related without the prospect of pass-
ing on problematic or dangerous conditions. To the ex-
tent these changes would persist across the generations,
it could benefit not only the immediate offspring, but
also all of the descendants of those who use the technol-
ogy. On the other hand, it is this same phenomenon —
of a change that reverberates down through the genera-
tions — that increases concern about unintended effects
whose disadvantages might grossly outweigh any advan-
tages that genome editing confers. And, because these
risks would be borne by those who had no say in the de-
cision, it eliminates the most common justification for
such actions — that is, that the risk-taker has made an
informed and voluntary decision to encounter the risk.
While this is certainly true in every case of parental
decision-making on behalf of a future or existing child,
in those situations the rearing parents will share with
the child both the risks and the possible benefits, thus
adding some situational constraints on rash action. But
when those risks and possible benefits are largely felt by
future generations, this constraint, in the form of self-
interest and self-protection, is removed.
Critics will also point to the intrinsic uncertainty about
downstream effects, and will invoke some form of the
precautionary principle [34], which demands a strong
justification before permitting any risk-creating activity,
with risk defined both in terms of known hazards and
unknown possibilities. The latter, of course, is incapable
of measurement, which is where the precautionary
principle can be stretched into a generalized prohibition.
In cases of devastating genetic diseases, some might
argue forcefully that the risks of editing procedures are
acceptable. At the same time, we must admit that we
cannot confidently predict all the consequences, whether
of introducing deleterious traits or by losing unantici-
pated benefits to retaining particular alleles. The hetero-
zygote advantage of the sickle cell hemoglobin mutation
in resisting malaria infection comes to mind.
As to the justification for taking risks, a variety of means
already exist to avoid passing on problematic traits, in-
cluding the choice to forego biological reproduction, the
use of donated gametes and embryos, or the use of pre-
implantation and prenatal diagnostic techniques to
avoid the birth of an affected child. Even while acknow-
ledging that the option of embryo selection or selective
abortion will be unacceptable or emotionally difficult
for many, the availability of these alternatives will be
seen as a means to diminish the prospective benefits of
gene editing, by measuring those benefits solely in terms
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outcomes.
Another thread in consequentialist argumentation
concerns the wisdom of any effort to alter the human
condition through genetic manipulation. Even before the
glimmerings of a theory of genetic inheritance, societies
across the world had eras in which they viewed selective
breeding as a means to ensure the superiority of any
resulting children. With the publication of Darwin’s
works, and their manipulation into social theory by Her-
bert Spencer, a new age of ‘scientific’ eugenics was born.
Couched in terms of social hygiene, it attracted followers
from all parts of the political spectrum and combined
crude understandings of genetics with a host of cultural
prejudices. Not surprisingly, it led to ugly decades of the
worst form of eugenics, with mass involuntary steriliza-
tions and mass murder [35]. Genome editing, like its less
efficient predecessors (including choice of gamete do-
nors, or pre-implantation selection of embryos), is tou-
ted by some for its potential to clear deleterious traits
from the family line, and criticized by others for its
echoes of simplistic and cruel notions of genetic super-
iority and inferiority [36].
Closely connected to these concerns, but with some
independent factors, is a second standard form of ethics
analysis, one that focuses less on specific consequences
and more on some set of fundamental principles of right
and wrong, or on spiritual and religious views about the
appropriate scope of human control over the planet and
the species. These categorical approaches are frequently
found in theological analyses of new biotechnologies.
For example, towards the end of Simon Mawer's 1998
novel, Mendel's Dwarf [37], the protagonist, a hereditary
dwarf, faces a choice:
"Benedict Lambert is sitting in his laboratory playing
God. He has eight embryos in eight little tubes. Four of
the embryos are proto-Benedicts, proto-dwarfs; the
other four are, for want of a better word, normal. How
should he choose?"
For those approaching the question from a religious
point of view, many see the act of choosing as a usurp-
ation of God’s role in mankind’s existence. During a
1997 consideration of cloning policy, for example, the
National Bioethics Advisory Commission (NBAC) [38]
listened as theologian Dr Gilbert Meilaender testified
that Protestants, although stout defenders of human
freedom, nonetheless "have not located the dignity of
human beings in a self-modifying freedom that knows
no limit, [not] even…God." Rev. Albert Moraczewski, a
Catholic, testified that cloning "exceed[s] the…delegated
dominion given to the human race. There is no evidence
that humans were given the power [by God] to altertheir nature or the manner in which they come into ex-
istence" [38]. But in the novel [37], Benedict's instinct
about God's role is somewhat different:
“Of course we all know that God has opted for the
easy way out. He has decided on chance.... You may…
select two of the four normal embryos and send them
over to the clinic for implantation …or…select the four
achondroplastics, the four stunted little beings…and
send them over instead…or… refuse to usurp the
powers of God and choose instead to become as
helpless as He…by choosing one normal embryo and
one achondroplastic and leaving the result to blind
and careless chance.”
It is evident that Americans do not share a common
view on the act of choice where creating and altering life
is concerned. While some see choosing as ‘playing God’,
others see it as ‘playing human’. Indeed, Rabbi Elliot
Dorff testified at that same NBAC meeting that we are
"the partner of God in the ongoing act of creation. We
are God's agent.... ". Examining Biblical texts, Rabbi
Moshe Tendler testified that being such a partner means
taking an active role, and that ‘artificiality’, far from being
wrong or evil, is rather a sign of humanity's constructive
contribution, a sign that we are doing our duty. Further-
more, a professor of Islamic studies, Aziz Sachedina, de-
scribed how the Koran suggests that "as participants in
the act of creating with God, God being the best of crea-
tors, human beings can actively engage in furthering the
overall state of humanity by intervening in the works of
nature, including the early stages of embryonic develop-
ment" when the goal is to achieve a natural good, such
as health or fertility [38].
It is equally evident that people around the globe do
not share a common view on the act of choice where
creating and altering life is concerned. In places such as
Singapore, China or Israel, attitudes about the moral and
legal significance of embryos and fetuses, and about the
appropriate degree of human control over its environ-
ment and its destiny, have been shaped by different
histories and religious traditions [39]. In Germany,
where the events of World War II still loom large in the
collective memory, anything that relates to genetics will
be met by skepticism, especially if there is any hint of
eugenics [40]. In France, the internal politics of a coun-
try dedicated to secularism since the 18th century but
with powerful church influences has led to a degree of
conservatism with respect to all forms of embryo re-
search, and will likely have the same effect on debates
about whether to make changes in the human germline
[41]. By contrast, the United Kingdom has spent decades
building a regulatory apparatus that is integrated with
public opinion and legislative oversight, and which is
Box 1. Gene drives
An additional use of genome editing, particularly of the
CRISPR-Cas tools, is envisioned in applications called synthetic
‘gene drives’ [45]. As a general term, gene drive refers to DNA
sequences — sometimes whole chromosome sets — that
increase the frequency of their own inheritance. There are
several natural examples, but the current discussion focuses on
the construction of such elements for the control of populations
of disease vectors [46] — for example, the tropical mosquitoes
that spread the malaria and dengue fever agents. The approach
would be, for example, to introduce into the Anopheles
genome a nuclease gene that cuts a crucial target — perhaps
a gene required for Plasmodium transmission. Upon cleavage,
copying of the nuclease’s own coding sequence into the
target site is stimulated. Not only would this inactivate the
target gene, the inherited allele would in turn induce copying
of the insertion into a vacant allele in the next generation.
Thus, the mutation would spread rapidly through the breeding
population.
There is appropriate concern that spread of the gene drive will
be difficult to control, and it might spread to populations or
have consequences beyond those intended [47]. Various
designs of the drive itself and other containment measures have
been proposed to prevent such escapes. While the gene drive
scheme could, in principle, be executed with any of the
nuclease platforms, it is again the efficacy and simplicity of
CRISPR-Cas that has suggested that such applications are close
at hand [48] and deserve careful examination.
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technologies, but even over every particular use of a
technology, down to the laboratory, clinic and patient,
something not often possible under the US system [42].
It should be no surprise, then, that the use of gene edit-
ing will likely proceed at wildly different rates among
countries, cultures and regulatory systems.
To address this reality, a small group of scientists,
lawyers and ethicists came together in early 2015 in
Napa, California. The discussion there led to a call for a
temporary moratorium on human applications of germ-
line editing [26]. This was quickly followed by an an-
nouncement by the National Academy of Sciences and
National Academy of Medicine that a joint initiative
would be undertaken, with two major activities [28].
The first, an international summit, would gather scien-
tists and thought leaders from around the globe, to dis-
cuss the state of the research around the world, to
compare regulatory and cultural approaches, and to
begin thinking about the kind of global norms that
might be most appropriate to this area. The second, a
study committee, will dig more deeply into the science,
with an eye to understanding probable applications,
their risks and benefits, and the applicable oversight
systems.
In advance of these deliberations, The Hinxton Group
[43], a self-organized international group of scientists
and ethicists, has recently issued a statement on gen-
ome editing technologies and human germline modifi-
cations. Like others who have entered this discussion,
they believe that technical advances are necessary before
human germline applications should be undertaken. At
the same time, they appear to make a tacit assumption
that such manipulations will ultimately go forward, and,
in this context, recommend that research on genome
editing in human embryos should proceed under strict
guidelines. While acknowledging the ethical concerns,
they caution against over-regulation, which could in-
hibit orderly progression towards legitimate uses of the
technology.
Even further along this path is the UK’s Human Em-
bryology and Fertilisation Authority, which is now con-
sidering a specific proposal for use of gene editing on
human embryos, in order to investigate the causes for
repeated miscarriages [44]. The British and American
systems of governance are quite different. In the USA,
this procedure would likely be under the jurisdiction of
the FDA, which would evaluate preclinical and clinical
research data for a particular indication. If approved,
the procedure could be advertised and promoted for
only that indication and patient population, but physi-
cians would have discretion to use it for indications or
types of patients other than those for which it was ap-
proved. By contrast, in the UK, control over use istighter — physicians and clinics must be licensed for
each application. This allows for more precise control
over dissemination of the technique, but at the cost of
losing a degree of professional independence and
judgment.Concluding thoughts
Genome editing, whether with ZFNs or TALENs or,
now, with CRISPR-Cas (see also Box 1), represents a
next step in our ability to analyze and alter the genetics
of plants and animals, including ourselves. The notion
that knowledge and the choices it offers might be our
downfall is as old as the biblical tale of the Garden of
Eden. But, in equal measure, history demonstrates the
enormous benefits in health and happiness that come
with responsible exercise of our intellect and powers of
invention. The newest developments in genome editing
will demand that we think again about how to balance
hope and fear.
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